Tumor mutational load is prognostic for progression to therapy among high-count monoclonal B-cell lymphocytosis (HCMBL).
Kleinstern G, Boddicker NJ, O'Brien DR, Allmer C, Rabe KG, Norman AD, Griffin R, Yan H, Ma T, Call TG, Bruins L, Brown S, Bonolo de Campos C, Hanson CA, Leis JF, Ding W, Vachon CM, Kay NE, Oakes CC, Parker A, Brander DM, Weinberg JB, Furman RR, Shanafelt TD, Cerhan JR, Parikh SA, Braggio E, Slager SL.
Kleinstern G, et al. Among authors: hanson ca.
Blood Adv. 2024 Feb 15;8(9):2118-29. doi: 10.1182/bloodadvances.2023012242. Online ahead of print.
Blood Adv. 2024.
PMID: 38359367
Free PMC article.